Market Highlights
Pharmacogenomics defines how genes can affect a person’s response to drugs. Pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The growing biotech industry boosts the market growth. According to the Organization for Economic Co-operation and Development in 2017, biotech R&D in the business enterprise sector was 11.3%, and 9.4% of total business enterprise R&D, for U.S. and France respectively in 2014.
The global pharmacogenomics market is expected to grow at a ~CAGR of 5.8% during the forecasted period.
Moreover, in 2016, according to the BIOCOM AG, the total turnover for the Germany based biotech companies was USD 3.7 billion. Moreover, rising healthcare expenditures followed by increasing interest for customized drugs will drive the market growth. However, lack of awareness and consistency in pharmacogenomics products will restrain the market growth during the forecasted period.
Segmentation
The global pharmacogenomics market is segmented on the basis of technology, application, and end user.
On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others. On the basis of application, the market is segmented into oncology, cardiology, neurological disorders, and others. The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others. On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others
Key Players
The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others
The pain management devices market is estimated to represent a global market of USD 8.1 billion by 2025 with growth rate of 10.9%.
However, high cost will hamper the market growth.Monoclonal Antibodies Market:The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%.
Due to this fact, I Met Jesus the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018.
TARGET AUDIENCETraders, Distributors, And SuppliersManufacturersGovernment and Regional Agencies and Research OrganizationsConsultantsDistributorsHospitalsThings You Should Know If You Are PregnantThe progression of new data and proposals for pregnant ladies can be overwhelming and confounding.
How about we figure out which beautifiers, food sources, beverages, methodology, and drugs are protected to use during your pregnancy and which can cause hurt.
Have you ever heard of maternity girdles?
This report aims to provide detailed insights into the NGS-based RNA-sequencing market.
It provides valuable information on the type, procedure, application, and region in the market.
Expected Revenue Growth: The NGS-based RNA-sequencing industry size is projected to reach USD 4.2 billion by 2024 from USD 1.7 billion in 2019, at a CAGR of 20.0% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816 Key Factors Driving Market Growth: Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market.
The expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing industry, by application, in 2018 Based on application, the NGS-Based RNA-Sequencing Market is segmented into expression profiling analysis, small RNA sequencing, De Novo transcriptome assembly, and variant calling & transcriptome epigenetics.
Nanopore sequencing technology registers the highest growth rate in the market as it is the only sequencing technology with direct RNA sequencing capabilities and facilitates sequencing of full-length RNA strands and modified RNA nucleotides using a simple library prep, without the need of conversion to double-stranded DNA.
